-
Mashup Score: 12
Program: Oral and Poster Abstracts Session: 704. Cellular Immunotherapies: Early Phase Clinical Trials and Toxicities: Poster III Hematology Disease Topics & Pathways: Adult, Clinical Practice (Health Services and Quality), Drug development, Treatment Considerations, Study Population, Human, Measurable Residual Disease Nelli Bejanyan, MD 1, Hany Elmariah, MD, MS 1, Jongphil Kim, PhD 2 *, Cheryl Cox 3 *, Melissa Lowden 4 *, Xiaofei Song, PhD 2 *, Hien Liu, MD 5, Bin Yu 6 *, Kayla Reid, MS 7 *, Sean J.
Source: ash.confex.comCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 8Paper: Patterns of Progression and Outcomes in Multiple Myeloma after Anti-BCMA CAR T-Cell Therapy - 13 day(s) ago
Program: Oral and Poster Abstracts Session: 653. Multiple Myeloma: Clinical and Epidemiological: Poster III Hematology Disease Topics & Pathways: Research, Adult, Clinical Research, Health outcomes research, Plasma Cell Disorders, Diseases, Real-world evidence, Lymphoid Malignancies, Study Population, Human 1 H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 2 Morsani College of Medicine, University of South Florida, Tampa, FL 3 Department of Hematology and Oncology, USF Morsani/H. Lee
Source: ash.confex.comCategories: General Medicine News, Oncologists1Tweet-
Tomorrow at #ASH24, join Ziad Abuhelwa, MD (@zabuhelwa) as he highlights the progression patterns and outcomes in multiple myeloma after anti-BCMA CAR T-cell therapy. Read more: https://t.co/e5sQM4t6fO @ASH_hematology #MoffittASH24 https://t.co/dTrXdeLGzF
-
-
Mashup Score: 9
Program: Oral a nd Poster Abstracts Session: 908. Outcomes Research: Myeloid Malignancies: Poster III Hematology Disease Topics & Pathways: Clinical Practice (Health Services and Quality), Diversity, Equity, and Inclusion (DEI) 1 Department of Oncological Sciences, H. Lee Moffitt Cancer Center, University of South Florida, ALBANY, NY 2 Department of Oncological Sciences, H. Lee Moffitt Cancer Center, University of South Florida, Tampa, FL 3 H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 4
Source: ash.confex.comCategories: General Medicine News, Oncologists1Tweet-
During #ASH24, Faustine Ong, MD (@faustine_ong) discusses disparities in AML survival in the targeted therapy era. Read more: https://t.co/9vtwS7WPUc @ASH_hematology #MoffittASH24 https://t.co/h2WZUDUCZj
-
-
Mashup Score: 13Moffitt at ASH - 14 day(s) ago
Moffitt Cancer Center is excited to once again participate at the 65th American Society of Hematology Meeting and Exposition to present some of our most innovative science in the area of hematologic malignancies. Find out more here.
Source: www.moffitt.orgCategories: General Medicine News, Oncologists1Tweet-
Join Moffitt Cancer Center experts during the #ASH24 poster hall session to explore our latest research and breakthroughs in hematology. Find the full list of presentations at https://t.co/jKoUQHUMY3. #MoffittASH24 https://t.co/6v9IzgsfOW
-
-
Mashup Score: 7Paper: Clinical Relevance of Subgrouping in TP53 mutated Myelodysplastic Neoplasms: Insights from ICC and Who Classifications - 14 day(s) ago
Program: Oral and Poster Abstracts Session: 637. Myelodysplastic Syndromes: Clinical and Epidemiological: Poster II Hematology Disease Topics & Pathways: Adult, Research, Genomics, Clinical Research, Hematopoiesis, Diseases, Biological Processes, Myeloid Malignancies, Technology and Procedures, Human, Study Population, Profiling, Pathogenesis, Molecular testing, Pathology 1 Hematopathology and Laboratory Medicine, Moffitt Cancer Center & Research Institute, Tampa, FL 2 Department of Pathology, H. Lee
Source: ash.confex.comCategories: General Medicine News, Oncologists1Tweet-
Join Hammad Tashkandi, MD (@hammadnmt) at #ASH24 for a discussion on the clinical relevance in classification methods and the prognostic implications of subgrouping within TP53-mutated myelodysplastic neoplasms as outlined by WHO and ICC. Read more: https://t.co/EkEBWDG7iV… https://t.co/NXIR2GPVev https://t.co/y1Eed4dSXj
-
-
Mashup Score: 12Paper: Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel - 14 day(s) ago
Program: Oral and Poster Abstracts Session: 907. Outcomes Research: Plasma Cell Disorders: Poster II Hematology Disease Topics & Pathways: Research, Adult, Epidemiology, Clinical Research, Plasma Cell Disorders, Health disparities research, Diseases, Real-world evidence, Lymphoid Malignancies, Study Population, Human Lauren C. Peres, PhD, MPH 1 *, Alicia Richards, PhD 1 *, Surbhi Sidana, MD 2, Laura B. Oswald, PhD 3 *, Danai Dima, MD 4, Aimaz Afrough, MD 5, Leyla O. Shune, MD 6, Shonali Midha, MD 7 *,
Source: ash.confex.comCategories: General Medicine News, Oncologists1Tweet-
At #ASH24, Lauren Peres, PhD (@LaurenPeresPhD) discusses racial and ethnic differences in outcomes of multiple myeloma patients treated with idecabtagene vicleucel or ciltacabtagene autoleucel. Read more: https://t.co/0xkmrtbbck @ASH_hematology #MoffittASH24 https://t.co/aaq4VPZoiM
-
-
Mashup Score: 13
Program: Oral and Poster Abstracts Type: Oral Session: 653. Multiple Myeloma: Clinical and Epidemiological: Exploring T Cell Redirecting Therapies, Mutation Profiles and Early Relapse Hematology Disease Topics & Pathways: Research, Translational Research, Clinical Practice (Health Services and Quality), Clinical Research, Health outcomes research, Plasma Cell Disorders, Diseases, Real-world evidence, Lymphoid Malignancies, Adverse Events Doris K. Hansen, MD 1, Ciara Louise Freeman, PhD, MSc, FRCPC, MRCP
Source: ash.confex.comCategories: General Medicine News, Oncologists1Tweet-
At #ASH24, Doris Hansen, MD highlights discusses a comprehensive analysis of pre-treatment biomarkers associated with toxicity and durable response in idecabtagene vicleucel therapy for relapsed/refractory #MultipleMyeloma patients. Read more: https://t.co/IHpn3uYz9l… https://t.co/wp0s6Jw0Aq https://t.co/nig6iJPDdu
-
-
Mashup Score: 14
Program: Oral and Poster Abstracts Type: Oral Session: 627. Aggressive Lymphomas: Pharmacologic Therapies: Novel Monotherapies or Novel Disease Indications Hematology Disease Topics & Pathways: Research, Clinical trials, Lymphomas, Bispecific Antibody Therapy, Clinical Research, B Cell lymphoma, Diseases, Treatment Considerations, Biological therapies, Lymphoid Malignancies Sameh Gaballa, MD 1, Jing-Zhou Hou, MD, PhD 2, Sumana Devata, MD 3, Seok-Goo Cho 4 *, Ranjit Nair, MD 5, Dok Hyun Yoon, MD, PhD 6,
Source: ash.confex.comCategories: General Medicine News, Oncologists1Tweet-
Sameh Gaballa, MD shares at #ASH24 that AZD0486 demonstrates high response rates in relapsed/refractory diffuse large B-cell lymphoma, including patients who failed CAR-T therapy. Read more: https://t.co/hI3ewo8PBN… @ASH_hematology #MoffittASH24 https://t.co/DKOSAK5Llf
-
-
Mashup Score: 7Paper: U.S. Expert Consensus on Defining Intolerance to Tyrosine Kinase Inhibitor Treatment in Chronic Phase Chronic Myeloid Leukemia (CML) - 14 day(s) ago
Program: Oral and Poster Abstracts Session: 903. Health Services and Quality Improvement: Myeloid Malignancies: Poster III Hematology Disease Topics & Pathways: Adult, Clinical Practice (Health Services and Quality), CML, Chronic Myeloid Malignancies, Diseases, Adverse Events, Myeloid Malignancies, Human 1 Medical College of Wisconsin, Milwaukee, WI 2 PHAR (Partnership for Health Analytic Research), Beverly Hills, CA 3 Moffitt Cancer Center, Tampa, FL 4 Huntsman Cancer Institute, University of Utah, Salt
Source: ash.confex.comCategories: General Medicine News, Oncologists1Tweet-
At #ASH24, Onyee Chan, MD presents the U.S. expert consensus on defining intolerance to tyrosine kinase inhibitor treatment in chronic phase chronic myeloid leukemia. Read more: https://t.co/dScBvkvCsa @ASH_hematology https://t.co/W5wHv3IdSw
-
-
Mashup Score: 162Paper: Phase 1/1b Dose Escalation and Expansion of CPX-351 in Combination with Gemtuzumab Ozogamicin in Newly Diagnosed Acute Myeloid Leukemia - 14 day(s) ago
Program: Oral and Poster Abstracts Session: 617. Acute Myeloid Leukemias: Commercially Available Therapies: Poster III Hematology Disease Topics & Pathways: Research, Clinical trials, Acute Myeloid Malignancies, AML, Combination therapy, Adult, Clinical Research, Diseases, Treatment Considerations, Adverse Events, Myeloid Malignancies, Study Population, Human 1 Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL 2 AbbVie, Inc., Collierville, TN 3 Department of Oncological Sciences, H. Lee
Source: ash.confex.comCategories: General Medicine News, Oncologists1Tweet-
During #ASH24, Onyee Chan, MD presents on phase 1/1b dose escalation and expansion of CPX-351 in combination with gemtuzumab ozogamicin in newly diagnosed acute myeloid leukemia. Read more: https://t.co/LTqnCoHdWu @ASH_hematology #MoffittASH24 https://t.co/fv0UGk9aFz
-
At #ASH24, Nelli Bejanyan, MD presents the findings of a first-in-human trial using expanded donor gamma delta T cell immunotherapy to prevent acute myeloid leukemia relapse after allogeneic transplantation. Read more: https://t.co/YEXVvJ01c6 @ASH_hematology #MoffittASH24 https://t.co/a91Z9fga0h